ClinicalTrials.gg
CompletedNCT03877510Updated Jul 13, 2023Results posted

Open Label Extension (OLE) Study of the Safety and Clinical Utility of IPX203 in Parkinson's Disease (PD) Participants With Motor Fluctuations

A Phase 3 interventional study of IPX203 in Parkinson Disease, sponsored by Impax Laboratories, LLC. Completed at 98 sites in 8 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2023-07-13.

Sponsored by Impax Laboratories, LLC (part of Amneal Pharmaceuticals, Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
419
Allocation
Not applicable
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. — 1 open to participants now, 1 under way, none of them phase 3. Parkinson Disease · Amneal Pharmaceuticals, Inc..

Enrollment
4th of 14
419 · median 77
Started
2019
the only one that year
Phase 3
7 of 14
none open now
Registered
13th of 14
by date

Among the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., this one is the 4th largest by enrollment, is the only one that started in 2019, is one of 7 in phase 3, and was the 13th registered.

Parkinson Disease

4,578 studies on the registry are indexed under Parkinson Disease; 1,085 are open to participants now.

Browse Parkinson Disease studies →

Open to participants now

1 of the 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc. is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 748 Parkinson Disease studies recruiting now, 311 (42%) set no upper age limit and 127 (17%) stop at 75 or younger; 64 take children under 18; 189 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies in Parkinson Disease by Amneal Pharmaceuticals, Inc., or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the long-term safety and clinical utility of IPX203 in the treatment of participants with advanced Parkinson's disease (PD) who have motor fluctuations.

Read the detailed description

This is a 9-month, multicenter open-label safety extension study. Participants who have successfully completed Study NCT03670953 [A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release (IR) Carbidopa-Levodopa (CD-LD) in Parkinson's Disease Patients with Motor Fluctuations] may have the opportunity to enroll in this open-label study.

03

Conditions studied

  • Parkinson Disease

Browse trials for

Keywords

  • motor fluctuations
  • IPX203
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Successfully completed Study IPX203-B16-02
  • Able to provide written prior to the conduct of any study-specific procedures.
  • Female participants of must have a negative urine pregnancy test at the baseline visit (Visit 1).
  • Agrees to use a medically acceptable method of throughout the study and for 6 weeks after completing the study.

Exclusion criteria

Exclusion Criteria:

  • Intends to use any doses of Rytary® or Duopa™ during this study.
  • Plans to use an treatment other than IPX203 during the course of this study.
  • Neurosurgical ablation treatment for PD is planned or anticipated during the study period. Implantation of a deep brain stimulator (DBS) for the treatment of PD is permitted during this study.
  • Participants who, in the opinion of the clinical investigator, should not participate in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
419 participants (actual)

Study arms

  • Experimental
    Open Label IPX203

    All participants received oral administration of extended-release capsules IPX203 dosing regimen that was determined at the end of the IPX203 dose conversion period of Study IPX203-B16-02 (NCT03670953) for nine months of open-label therapy. The dose and dosing frequency was determined by the investigator to achieve the optimal balance of efficacy and safety.

    Drug: IPX203

Interventions

  • DrugIPX203

    IPX203 extended release capsules

06

What researchers measure

Primary outcomes

  1. Number of Participants With Treatment-Emergent Adverse Events

    An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was considered as treatment-emergent if the date of onset was on or after the date of the first open-label study drug administration in this Study IPX203-B16-03 and no later than 1 day after the last study drug dose in the study.

    Time frame: From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])

Secondary outcomes

  1. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260).

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  2. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260).

    Time frame: Baseline, Month 9/ET

  3. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  4. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

    Time frame: Baseline, Month 9/ET

  5. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  6. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

    Time frame: Baseline, Month 9/ET

  7. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  8. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD.

    Time frame: Baseline, Month 9/ET

  9. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  10. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD.

    Time frame: Baseline, Month 9/ET

  11. Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  12. Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III

    MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD.

    Time frame: Baseline, Month 9/ET

  13. Patient Global Impression of Severity (PGI-S)

    The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  14. Change From Baseline in Patient Global Impression of Severity (PGI-S)

    The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.

    Time frame: Baseline, Month 9/ET

  15. Percentage of Participants With a PGI-S ≥ 4 and PGI-S ≥ 5

    The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  16. Clinical Global Impression of Severity (CGI-S)

    The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.

    Time frame: Baseline, Month 3, Month 6, Month 9/ET

  17. Change From Baseline in Clinical Global Impression of Severity (CGI-S)

    The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.

    Time frame: Baseline, Month 9/ET

  18. Percentage of Participants With a CGI-S ≥ 4 and CGI-S ≥ 5

    The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  19. 39-item Parkinson's Disease Questionnaire (PDQ-39): Total

    The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  20. Change From Baseline in PDQ-39: Total

    The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness.

    Time frame: Baseline, Month 9/ET

  21. Parkinson Anxiety Scale (PAS): Total

    The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  22. Change From Baseline in Parkinson Anxiety Scale (PAS): Total

    The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms.

    Time frame: Baseline, Month 9/ET

  23. Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total

    The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  24. Change From Baseline in Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total

    The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score.

    Time frame: Baseline, Month 9/ET

  25. Parkinson's Disease Sleep Scale-2 (PDSS-2) Total

    The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60.

    Time frame: Baseline, Month 3, Month 6, and Month 9/ET

  26. Change From Baseline in Parkinson's Disease Sleep Scale-2 (PDSS-2):Total

    The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60.

    Time frame: Baseline, Month 9/ET

  27. Treatment Satisfaction Assessment (TSA)

    The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied.

    Time frame: Month 3, Month 6 and Month 9/ET

  28. Percentage of Participants With TSA Scores 5-7 (Satisfied) Versus Scores 1-4 (Dissatisfied or Neutral)

    The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied.

    Time frame: Month 3, Month 6, and Month 9/ET

07

Results

Posted Jun 6, 2023

Participant flow

Participants who successfully completed Study IPX203-B16-02 (NCT03670953) had the opportunity to enroll in the 9-month, open-label safety extension IPX203-B16-03 (NCT03877510) study. A total of 419 participants were enrolled.

Participant flow — Overall Study
MilestoneOpen Label IPX203
Started419
Completed352
Not completed67
Withdrew: Death6
Withdrew: Lost to follow-up2
Withdrew: Non-compliance with study drug2
Withdrew: Lack of efficacy14
Withdrew: Adverse event20
Withdrew: Withdrawal by subject22
Withdrew: Miscellaneous1

Outcome measures

PrimaryNumber of Participants With Treatment-Emergent Adverse Events

An adverse event (AE) is any untoward medical occurrence in a participant or clinical trial participant administered a medicinal product and which does not necessarily have to have a causal relationship with this treatment. An adverse event can therefore be any unfavorable and unintended sign (e.g., an abnormal laboratory finding), symptom, or disease temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE was considered as treatment-emergent if the date of onset was on or after the date of the first open-label study drug administration in this Study IPX203-B16-03 and no later than 1 day after the last study drug dose in the study.

Time frame:
From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET])
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events
ParticipantsOpen Label IPX203
Number of Participants With Treatment-Emergent Adverse Events221
SecondaryMovement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260).

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total
score on a scaleOpen Label IPX203
Baseline56.7 ± 28.64
Month 356.5 ± 30.14
Month 656.0 ± 28.92
Month 9/ET59.0 ± 29.11
SecondaryChange From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260).

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total
score on a scaleOpen Label IPX203
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Total2.7 ± 16.44
SecondaryMovement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I
score on a scaleOpen Label IPX203
Baseline9.9 ± 6.27
Month 310.6 ± 6.43
Month 610.7 ± 6.21
Month 9/ET11.0 ± 6.72
SecondaryChange From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part I score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I
score on a scaleOpen Label IPX203
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part I1.2 ± 4.56
SecondaryMovement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II
score on a scaleOpen Label IPX203
Baseline12.8 ± 7.83
Month 313.0 ± 7.96
Month 612.8 ± 7.69
Month 9/ET13.6 ± 8.11
SecondaryChange From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part II score ranges from 0 to 52. A higher score indicated more severe symptoms of PD.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II
score on a scaleOpen Label IPX203
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part II0.9 ± 4.81
SecondaryMovement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III
score on a scaleOpen Label IPX203
Baseline27.5 ± 17.23
Month 326.8 ± 17.90
Month 626.6 ± 17.50
Month 9/ET27.8 ± 16.79
SecondaryChange From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part III score ranges from 0 to 132. A higher score indicated more severe symptoms of PD.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III
score on a scaleOpen Label IPX203
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part III0.6 ± 11.29
SecondaryMovement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV
score on a scaleOpen Label IPX203
Baseline6.6 ± 2.96
Month 36.0 ± 3.15
Month 66.0 ± 3.08
Month 9/ET6.6 ± 3.34
SecondaryChange From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). Part IV score ranges from 0 to 24. A higher score indicated more severe symptoms of PD.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV
score on a scaleOpen Label IPX203
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Part IV0.0 ± 2.64
SecondaryMovement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III
score on a scaleOpen Label IPX203
Baseline40.3 ± 23.09
Month 339.8 ± 24.15
Month 639.4 ± 23.24
Month 9/ET41.5 ± 22.96
SecondaryChange From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III

MDS-UPDRS is a multimodal scale assessing impairment and disability consisting of 4 parts. (Part I; 13 items) non-motor experiences of daily living, (Part II; 13 items) motor experiences of daily living completed by the participants, (Part III; 33 items) motor examination of PD and was administered by the rater, and (Part IV; 6 items) motor complication integrates participant-derived information with the rater's clinical observations and judgements and is completed by the rater. For each question a numeric score was assigned between 0-4, where 0 = Normal, 1 = Slight, 2 = Mild, 3 = Moderate, 4 = Severe. MDS-UPDRS Total Score equals the sum of Parts I, II, and III and IV (Range 0-260). The scale range for Part II+III score is 0-184. A higher score indicated more severe symptoms of PD.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III
score on a scaleOpen Label IPX203
Change From Baseline in Movement Disorders Society Version of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): Sums of Part II and Part III1.5 ± 13.66
SecondaryPatient Global Impression of Severity (PGI-S)

The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
Patient Global Impression of Severity (PGI-S)
score on a scaleOpen Label IPX203
Baseline3.7 ± 1.02
Month 33.8 ± 1.00
Month 63.7 ± 0.99
Month 9/ET3.8 ± 1.12
SecondaryChange From Baseline in Patient Global Impression of Severity (PGI-S)

The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Patient Global Impression of Severity (PGI-S)
score on a scaleOpen Label IPX203
Change From Baseline in Patient Global Impression of Severity (PGI-S)0.0 ± 1.07
SecondaryPercentage of Participants With a PGI-S ≥ 4 and PGI-S ≥ 5

The PGI-S is a participant answered assessment rating Parkinson's disease severity on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Extremely severely ill.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Number · Percentage of Participants
Percentage of Participants With a PGI-S ≥ 4 and PGI-S ≥ 5
Percentage of ParticipantsOpen Label IPX203
Baseline PGI-S ≥ 464.5
Baseline PGI-S ≥ 520.3
Month 3 PGI-S ≥ 466.7
Month 3 PGI-S ≥ 520.0
Month 6 PGI-S ≥ 462.5
Month 6 PGI-S ≥ 520.7
Month 9/ET PGI-S ≥ 465.4
Month 9/ET PGI-S ≥ 522.6
SecondaryClinical Global Impression of Severity (CGI-S)

The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.

Time frame:
Baseline, Month 3, Month 6, Month 9/ET
Reported as:
Mean · score on a scale
Clinical Global Impression of Severity (CGI-S)
score on a scaleOpen Label IPX203
Baseline3.8 ± 0.87
Month 33.8 ± 0.92
Month 63.7 ± 0.87
Month 9/ET3.8 ± 0.97
SecondaryChange From Baseline in Clinical Global Impression of Severity (CGI-S)

The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Clinical Global Impression of Severity (CGI-S)
score on a scaleOpen Label IPX203
Change From Baseline in Clinical Global Impression of Severity (CGI-S)0.0 ± 0.81
SecondaryPercentage of Participants With a CGI-S ≥ 4 and CGI-S ≥ 5

The CGI-S is a clinician scale rating the severity of the participant's illness on a scale of 1 to 7; 1-Normal, not at all ill, 2-Borderline ill, 3-Mildly ill, 4-Moderately ill, 5-Markedly ill, 6-Severely ill, 7-Among the most extremely ill of participants.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Number · Percentage of participants
Percentage of Participants With a CGI-S ≥ 4 and CGI-S ≥ 5
Percentage of participantsOpen Label IPX203
Baseline CGI-S ≥ 466.7
Baseline CGI-S ≥ 519.6
Month 3 CGI-S ≥ 464.8
Month 3 CGI-S ≥ 518.3
Month 6 CGI-S ≥ 461.2
Month 6 CGI-S ≥ 514.0
Month 9/ET CGI-S ≥ 465.3
Month 9/ET CGI-S ≥ 517.6
Secondary39-item Parkinson's Disease Questionnaire (PDQ-39): Total

The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
39-item Parkinson's Disease Questionnaire (PDQ-39): Total
score on a scaleOpen Label IPX203
Baseline41.7 ± 27.71
Month 342.7 ± 27.73
Month 642.8 ± 28.15
Month 9/ET45.1 ± 29.45
SecondaryChange From Baseline in PDQ-39: Total

The PDQ-39 is a self-reported outcome of 39 questions relating to 8 domains: mobility (Questions 1-10), activities of daily living (ADL) (Questions 11-16), emotional well-being (Questions 17-22), stigma (Questions 23-26), social support (Questions 27-29), cognition (Questions 30-33), communication (Questions 34-36) and bodily discomfort (Questions 37-39). Each question is answered on a 5-point scale from 0 (Never) to 4 (Always / Cannot Do At All). Scores are calculated by summing the answers to the questions in the domain and converting to a scale from 0 to 100. Higher scores are associated with the more severe symptoms of the disease such as tremor and stiffness.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in PDQ-39: Total
score on a scaleOpen Label IPX203
Change From Baseline in PDQ-39: Total4.4 ± 18.65
SecondaryParkinson Anxiety Scale (PAS): Total

The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
Parkinson Anxiety Scale (PAS): Total
score on a scaleOpen Label IPX203
Baseline10.4 ± 8.18
Month 310.3 ± 8.20
Month 610.3 ± 7.67
Month 9/ET11.1 ± 8.57
SecondaryChange From Baseline in Parkinson Anxiety Scale (PAS): Total

The PAS is a three part participant answered assessment. Part 1 has 5 questions measuring persistent anxiety. Each question ranges from 0 - not at all, or never to 4 severe, or nearly always. Best score is 0; worst score is 20. Part 2 has 4 questions measuring episodic anxiety. Each question ranges from 0 - never to 4 - nearly always. Best score is 0; worst score is 16. Part 3 has 3 questions measuring avoidance behavior. Each question ranges from 0, never to 4 nearly always. Best score is 0; worst score is 12. Totals for all three parts are summed and ranges from 0 to 48, higher scores are associated with the more severe symptoms.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Parkinson Anxiety Scale (PAS): Total
score on a scaleOpen Label IPX203
Change From Baseline in Parkinson Anxiety Scale (PAS): Total0.9 ± 6.41
SecondaryNon-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total

The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total
score on a scaleOpen Label IPX203
Baseline32.0 ± 28.95
Month 332.5 ± 28.49
Month 633.4 ± 29.19
Month 9/ET35.3 ± 30.08
SecondaryChange From Baseline in Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total

The NMSS assesses non-motor symptoms in Parkinson's Disease. It consists of 30 questions grouped into 9 domains: cardiovascular, sleep/fatigue, mood/cognition, perceptual problems/hallucinations, attention/memory, gastro-intestinal tract, urinary, sexual function, and miscellaneous. Severity symptoms are rated on a scale of 0-3 with 3 being most severe; and frequency on a scale of 1-4 with 4 being most frequent. Each question is answered with a severity and frequency rating which are then multiplied. The sum of the products gives the total score which ranges from 0 to 360 with a lower score more desirable than a higher score.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total
score on a scaleOpen Label IPX203
Change From Baseline in Non-Motor Symptom Assessment Scale (NMSS) for Parkinson's Disease (PD): Total3.8 ± 22.33
SecondaryParkinson's Disease Sleep Scale-2 (PDSS-2) Total

The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60.

Time frame:
Baseline, Month 3, Month 6, and Month 9/ET
Reported as:
Mean · score on a scale
Parkinson's Disease Sleep Scale-2 (PDSS-2) Total
score on a scaleOpen Label IPX203
Baseline16.6 ± 9.72
Month 315.8 ± 9.16
Month 616.1 ± 9.29
Month 9/ET16.2 ± 9.28
SecondaryChange From Baseline in Parkinson's Disease Sleep Scale-2 (PDSS-2):Total

The PDSS-2 is a 15 question participant response scale measuring the severity of sleep disturbance. Three domains are defined: disturbed sleep (Questions 1-3, 8, 14), motor symptoms at night (Questions 4-6, 12, 13), PD symptoms at night (Questions 7, 9-11, 15). Each question is rated as very often to never on a scale of 0-4. The best overall score is 0; the worst overall score is 60.

Time frame:
Baseline, Month 9/ET
Reported as:
Mean · score on a scale
Change From Baseline in Parkinson's Disease Sleep Scale-2 (PDSS-2):Total
score on a scaleOpen Label IPX203
Change From Baseline in Parkinson's Disease Sleep Scale-2 (PDSS-2):Total-0.1 ± 8.92
SecondaryTreatment Satisfaction Assessment (TSA)

The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied.

Time frame:
Month 3, Month 6 and Month 9/ET
Reported as:
Mean · score on a scale
Treatment Satisfaction Assessment (TSA)
score on a scaleOpen Label IPX203
Month 35.2 ± 1.25
Month 65.4 ± 1.19
Month 9/ET5.2 ± 1.39
SecondaryPercentage of Participants With TSA Scores 5-7 (Satisfied) Versus Scores 1-4 (Dissatisfied or Neutral)

The TSA is a participant answered assessment rating treatment satisfaction on a scale of 1 to 7; 1 = Very much dissatisfied being least satisfied and 7 = Very much satisfied.

Time frame:
Month 3, Month 6, and Month 9/ET
Reported as:
Number · Percentage of Participants
Percentage of Participants With TSA Scores 5-7 (Satisfied) Versus Scores 1-4 (Dissatisfied or Neutral)
Percentage of ParticipantsOpen Label IPX203
Month 3: Percentage of TSA Scores 1-4 (Dissatisfied or Neutral)19.6
Month 3: Percentage of TSA Scores 5-7 (Satisfied)80.4
Month 6: Percentage of TSA Scores 1-4 (Dissatisfied or Neutral)15.6
Month 6: Percentage of TSA Scores 5-7 (Satisfied)84.4
Month 9/ET: Percentage of TSA Scores 1-4 (Dissatisfied or Neutral)23.7
Month 9/ET: Percentage of TSA Scores 5-7 (Satisfied)76.3

Adverse events

Collected over From first dose up to 1 day after last dose (Up to 9 months/Early Termination [ET]). Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Open Label IPX2036/419 (1.4%)42/419 (10%)99/419 (23.6%)
Most frequent serious events
Showing 10 of 59
Most frequent serious events
EventOpen Label IPX203
COVID-19Infections and infestations3/419
SeizureNervous system disorders3/419
Confusional statePsychiatric disorders3/419
Atrial fibrillationCardiac disorders2/419
VolvulusGastrointestinal disorders2/419
PneumoniaInfections and infestations2/419
Femur fractureInjury, poisoning and procedural complications2/419
SyncopeNervous system disorders2/419
Psychotic disorderPsychiatric disorders2/419
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders2/419
Most frequent other events
Most frequent other events
EventOpen Label IPX203
Urinary tract infectionInfections and infestations21/419
FallInjury, poisoning and procedural complications21/419
DyskinesiaNervous system disorders21/419
Back painMusculoskeletal and connective tissue disorders15/419
ConstipationGastrointestinal disorders11/419
COVID-19Infections and infestations10/419

Baseline characteristics

The Safety Analysis Set included all participants who were treated with the open-label study drug in the study.

Age, Continuous
Age, Continuous(years)Open Label IPX203
Mean66.9 ± 8.86
Sex: Female, Male
Sex: Female, Male(Participants)Open Label IPX203
Female140
Male279
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Open Label IPX203
Hispanic or Latino46
Not Hispanic or Latino369
Unknown or Not Reported4
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Open Label IPX203
American Indian or Alaska Native0
Asian6
Native Hawaiian or Other Pacific Islander0
Black or African American4
White406
More than one race0
Unknown or Not Reported3
08

Study locations

98 sites
  • Xenoscience, Inc (102)
    Phoenix, Arizona 85004, United States
  • St. Joseph's Hospital & Medical Center - Barrow Neurological Institute (156)
    Phoenix, Arizona 85013, United States
  • Clinical Trials, Inc (113)
    Little Rock, Arkansas 72205, United States
  • University of Arkansas for Medical Sciences (117)
    Little Rock, Arkansas 72205, United States
  • Keek School of Medicine of USC/ University of Southern California (106)
    Los Angeles, California 90033, United States
  • Hoag Memorial Hospital Presbyterian (134)
    Newport Beach, California 92663, United States
  • SC3 Research-Pasadena (148)
    Pasadena, California 91105, United States
  • SC3 Research-Reseda (146)
    Reseda, California 91335, United States
  • University of Colorado Hospital Anschutz Outpatient Pavilion (120)
    Aurora, Colorado 80045, United States
  • Rocky Mountain Movement Disorders (116)
    Englewood, Colorado 80113, United States
  • ChristianaCare Neurology Specialists (153)
    Newark, Delaware 19713, United States
  • JEM Research Institute (136)
    Atlantis, Florida 33462, United States
  • Visionary Investigators Network (168)
    Aventura, Florida 33180, United States
  • UHealth at Boca Raton (152)
    Boca Raton, Florida 33431, United States
  • Parkinson's Disease and Movement Disorders Center of Boca Raton (121)
    Boca Raton, Florida 33486, United States
  • Infinity Clinical Research LLC (104)
    Hollywood, Florida 33024, United States
  • University of Florida Health Science Center (129)
    Jacksonville, Florida 32209, United States
  • Neurology Associates, P.A. (125)
    Maitland, Florida 32751, United States
  • University of Miami (149)
    Miami, Florida 33136, United States
  • Medical Professional Clinical Research Center, Inc. (163)
    Miami, Florida 33165, United States
  • Parkinson's Disease Treatment Center of Southwest Florida (131)
    Port Charlotte, Florida 33980, United States
  • Infinity Clinical Research, LLC (105)
    Sunrise, Florida 33351, United States
  • University of South Florida (114)
    Tampa, Florida 33615, United States
  • Premiere Research Institute at Palm Beach Neurology (174)
    West Palm Beach, Florida 33407, United States
  • Charter Research (166)
    Winter Park, Florida 32792, United States
  • Emory Brain Health Center (110)
    Atlanta, Georgia 30329, United States
  • NeuroStudies.net, LLC (155)
    Decatur, Georgia 30033, United States
  • Northwestern Medical Group Neurology Clinic (145)
    Chicago, Illinois 60611, United States
  • Central DuPage Hospital (151)
    Winfield, Illinois 60190, United States
  • Indiana University Health Neuroscience Center(164)
    Indianapolis, Indiana 46202, United States
  • University of Kansas Medical Center (118)
    Kansas City, Kansas 66160, United States
  • Quest Research Institute (103)
    Farmington Hills, Michigan 48334, United States
  • Henry Ford West Bloomfield Hospital(100)
    West Bloomfield, Michigan 48322, United States
  • Washington University (109)
    Saint Louis, Missouri 63110, United States
  • Roseman Medical Research Institute / Roseman Medical Group (154)
    Las Vegas, Nevada 17601, United States
  • Cleveland Clinic Lou Ruvo Center for Brain Health (142)
    Las Vegas, Nevada 89106, United States
  • Albany Medical College (139)
    Albany, New York 12208, United States
  • Ucgni (133)
    Cincinnati, Ohio 45219, United States
  • University Hospitals Cleveland Medical Center (123)
    Cleveland, Ohio 44106, United States
  • Cleveland Clinic(144)
    Cleveland, Ohio 44195, United States
  • University of Toledo, Gardner-McMaster Parkinson Center (122)
    Toledo, Ohio 43614, United States
  • The Movement Disorder Clinic of Oklahoma (115)
    Tulsa, Oklahoma 74136, United States
  • The Vanderbilt Clinic (158)
    Nashville, Tennessee 37232, United States
  • Neurology Consultants of Dallas, PA (108)
    Dallas, Texas 75251, United States
  • University of Texas Southwestern Medical Center (143)
    Dallas, Texas 75390-9184, United States
  • Houston Methodist Neurological Institute/Movement Disorders Clinic (135)
    Houston, Texas 77030, United States
  • Inova Neurology- Fairfax (147)
    Fairfax, Virginia 17601, United States
  • VCU Health- Neuroscience Orthopaedic and Wellness Center(124)
    Henrico, Virginia 23233, United States
  • Booth Gardner Parkinson's Care Center (112)
    Kirkland, Washington 98034, United States
  • Inland Northwest Research (119)
    Spokane, Washington 99202, United States
  • Fakultni nemocnice u sv. Anny v Brne, I. neurologicka klinika (704)
    Brno, 65691, Czechia
  • NEUROHK. s.r.o. (701)
    Choceň, 56501, Czechia
  • Nemocnice Pardubickeho kraje, a.s., Pardubicka nemocnice, Neurologicka klinika (702)
    Pardubice, 53203, Czechia
  • CLINTRIAL s.r.o. (703)
    Praha 10, 10000, Czechia
  • AXON Clinical. s.r.o. (700)
    Praha 5, 15000, Czechia
  • Neurologicka ordinace FORBELI s.r.o. (706)
    Praha 6, 16000, Czechia
  • CHU de Clermont-Ferrand-Hopital Gabriel Montpied (404)
    Clermont-Ferrand Cedex 1, 63003, France
  • CHU de Montpellier, Hopital Gui de Chauliac (405)
    Montpellier Cedex 5, 34295, France
  • Centre Hospitalier Universitaire de Nice (400)
    Nice, 06002, France
  • Centre d'lnvestigation Clinique 1436- CHU Purpan- Hopital Pierre Paul Riquet (403)
    Toulouse Cedex 9, 31059, France
  • Kliniken Beelitz GmbH, neurologisches Fachkrankenhaus fur Bewegungsstorungen/Parkinson (300)
    Beelitz-Heilstätten, Beelitz 14547, Germany
  • St. Josef-Hospital, Universitatsklinik fur Neurologie Klinisches Forschungszentrum fur Neurodegeneration (301)
    Bochum, Gudrunstabe 56 44791, Germany
  • Klinikum rechts der lsar der Technischen Universitat Munchen Klinik und Poliklinik fur Neurologie (303)
    München, Ismaningerstrabe 81675, Germany
  • Dr. med. Reinhardt Ehret Neuroloqie Berlin Schlobstr. 29 (309)
    Berlin, 12163, Germany
  • Klinik Haag i. OB Geriatric Hospital Krankenhausstrabe 4 (305)
    Haag In Oberbayern, 83527, Germany
  • Gemeinschaftspraxis Dr. med. J. Springub/W. Schwarz, Studienzentrum Nordwest (306)
    Westerstede, 26655, Germany
  • Centro Ricerca Parkinson San Raffaele Cassino (601)
    Cassino, Frosinone 03043, Italy
  • Università G. D'annunzio CeSi Met (604)
    Chieti, Italy/Chieti/Abbruzzo 66100, Italy
  • Fondazione I st ituto Neurologico Nazionale "C. Mondino" (606)
    Pavia, Italy/Pavia/Lombardia 27100, Italy
  • Azienda Ospedaliero-Universitaria Pisana (602)
    Pisa, Italy/Pisa/Toscana 56126, Italy
  • IRCCS San Raffaele Pi sana (600)
    Roma, Italy/Roma/Lazio 00163, Italy
  • Department of neuroscience, mental health and sensory system (NeSMOS), "Sapienza" University (603)
    Roma, Italy/Roma/Lazio 00189, Italy
  • University of Rome Tor Vergata/Hospital Tor Vergata (605)
    Roma, Lazio 00133, Italy
  • Department "G. F. Ingrassia" section of neuroscience - Policlinico "Vittorio Emanuele" (608)
    Catania, Sicily 95123, Italy
  • Centrum Medyczne Neuromed (803)
    Bydgoszcz, 85163, Poland
  • Centrum Medyczne Linden (805)
    Kraków, 30721, Poland
  • Krakowska Akademia Neurologii Sp. Zo.o.(802)
    Kraków, 31-505, Poland
  • NZOZ Neuromed M. i M. Nastaj Sp.p. (800)
    Lublin, 20-064, Poland
  • NZOZ Neuro-Kard Ilkowski i Partnerzy Spolka Partnerska Lekarzy (801)
    Poznań, 61853, Poland
  • Neuro-Care Sp. z o.o. sp. k. (804)
    Siemianowice Śląskie, 41100, Poland
  • Centrum Medycme NeuroProtect (806)
    Warszawa, 01-684, Poland
  • Hospital General Universitario de Elche (509)
    Elche, Alicante 03203, Spain
  • Hospital Universitari General de Catalunya (504)
    Sant Cugat Del Vallès, Barcelona 08195, Spain
  • Hospital Universitari Mutua Terrassa (506)
    Terrassa, Barcelona 08222, Spain
  • Policlinica Gipuzkoa, S.A (511)
    Donostia San Sebastian, Gipuzkoa 20014, Spain
  • Clinica Universidad de Navarra (512)
    Pamplona, Navarra 31008, Spain
  • Hospital Universitario Quiron Dexeus (501)
    Barcelona, 08028, Spain
  • Germanes Hospitalaries Del Sagrat Cor De Jesus Hospital Sant Rafael (516)
    Barcelona, 08035, Spain
  • Hospital Universitario Vall d'Hebron (505)
    Barcelona, 08035, Spain
  • Hospital de Ia Santa Creu i Sant Pau (502)
    Barcelona, 08041, Spain
  • Hospital Universitario de Ia Princesa (508)
    Madrid, 28006, Spain
  • Hospital Universitario Ramon y Cajal (500)
    Madrid, 28034, Spain
  • Hospital Universitario Infanta Sofia(513)
    Madrid, 28703, Spain
  • Hospital Universitario Virgen del Rocio (503)
    Sevilla, 41013, Spain
  • Hospital Universitario y Politecnico La Fe Avenida Fernando Abril Martorell (515)
    Valencia, 46026, Spain
  • Re:Cognition Health Ltd (205)
    Plymouth, Devon PL68BT, United Kingdom
  • Imperial College Healthcare NI-lS Trust (200)
    London, W68RF, United Kingdom
  • Re:Cognition Health Ltd (202)
    London, WlG9JF, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Mar 2022, 35 months.

Results were first posted in Jun 2023, 1 year 2 months after primary completion.

Of 39 industry-sponsored phase 3 interventional studies under Parkinson Disease, half reached primary completion within 31 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 54. This study's 35 months is above that.

Counting every sponsor, half of 67 studies reached it within 35 months; a quarter within 22 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 12, 2019
First posted
Mar 15, 2019
StartActual
Apr 3, 2019
Primary completionActual
Mar 21, 2022
CompletionActual
Mar 21, 2022
Results first posted
Jun 6, 2023
Last update
Jul 13, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 13, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03877510
Responsible party
Sponsor
First posted
Mar 15, 2019
Start date
Apr 3, 2019
Primary completion
Mar 21, 2022
Completion
Mar 21, 2022
Results posted
Jun 6, 2023
Last update
Jul 13, 2023

Study contacts

Impax Impax Study Director
study director · Impax Laboratories, LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IPX203

Start the discussion